Newsletter Tool

Weekly Digest

This Week

Jun 13, 2025

Genentech lays off 143 workers at South San Francisco campus

FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall

FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer

NATO for medicines? Pfizer CEO calls for higher drug spending outside US amid Trump’s MFN pricing push

Eli Lilly works out $650M Juvena pact to find muscle-boosting drugs

Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO

Diabetes patients who use GLP-1s may have a higher risk of serious eye disease: study

Featured

Genentech lays off 143 workers at South San Francisco campus

By Gabrielle Masson

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco.

FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall

By Ben Adams

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns.

FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer

By Angus Liu

After questioning the benefits of checkpoint inhibitors in stomach cancer cases without PD-L1 expression, the FDA has moved to restrict the use of Merck's and Bristol Myers Squibb's immunotherapies in those patients.

NATO for medicines? Pfizer CEO calls for higher drug spending outside US amid Trump’s MFN pricing push

By Angus Liu

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most favored nation” (MFN) policy, Pfizer CEO Albert Bourla is calling for a U.S. government-led push to increase overall drug spending outside the U.S.

Eli Lilly works out $650M Juvena pact to find muscle-boosting drugs

By Nick Paul Taylor

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.

Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO

By Conor Hale

Caris recently began rolling out its MI Cancer Seek companion diagnostic test for genomic tumor profiling.

Diabetes patients who use GLP-1s may have a higher risk of serious eye disease: study

By Zoey Becker

In the study, diabetes patients who took GLP-1s were twice as likely to develop neovascular age-related macular degeneration (nAMD) than those without GLP-1 exposure.

National Resilience will close 6 of its 10 plants and carry on as streamlined CDMO

By Kevin Dunleavy

National Resilience is consolidating its CDMO business, closing six of its plants and continuing to operate as a streamlined company at four sites, including its anchor facility in Cincinnati.

Study unpacks ‘new realm of biology,’ where missing Y chromosomes worsen cancer outcomes

By Darren Incorvaia

A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is connected with a higher risk of dying from cancer.

Growing Astellas looks to reap the rewards of uniting commercial strategy, medical affairs: exec

By Zoey Becker

Astellas chief commercial officer Claus Zieler recently donned a second hat as medical affairs officer, marking the last step of uniting the two business areas.

Fierce podcasts

Don’t miss an episode

Inside the evolving playbook for employee wellbeing

This week on "Podnosis," we explore how employers are rethinking their approach to employee wellbeing—integrating mental, physical and financial health strategies to better reach the people who need them most.